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Abstract
Pancreatic and colorectal carcinomas frequently ex-
press oncogenic/mutant K-Ras that contributes to
both tumorigenesis and clinically observed resistance
to radiation treatment. We have previously shown
that farnesyltransferase inhibitors (FTI) radiosensitize
many pancreatic and colorectal cancer cell lines that
express oncogenic K-ras at doses that inhibit the
prenylation and activation of H-Ras but not K-Ras. In
the present study, we have examined the mechanism
of FTI-mediated radiosensitization in cell lines that
express oncogenic K-Ras and found that wild-type
H-Ras is a contributor to radiation survival in tumor
cells that express oncogenic K-Ras. In these experi-
ments, inhibiting the expression of oncogenic K-Ras,
wild-type H-Ras, or epidermal growth factor receptor
(EGFR) led to similar levels of radiosensitization as
treatment with the FTI tipifarnib. Treatment with the
EGFR inhibitor gefitinib led to similar levels of radio-
sensitization, and the combinations of tipifarnib or
gefitinib plus inhibition of K-Ras, H-Ras, or EGFR ex-
pression did not provide additional radiosensitization
compared with tipifarnib or gefitinib alone. Finally,
supplementing culture medium with the EGFR ligand
transforming growth factor A was able to reverse the
radiosensitizing effect of inhibiting K-ras expression.
Taken together, these findings suggest that EGFR-
activated H-Ras signaling is initiated by oncogenic
K-Ras to promote radiation survival in pancreatic and
colorectal cancers.
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Introduction
Oncogenic (mutationally activated) Ras isoforms are found in
approximately 30% of humanmalignancies and play a critical
role in tumorigenesis and resistance of malignant neoplasms
to standard therapies such as chemotherapy and radiation (re-
viewed in Ref. [1]). In addition, wild-type Ras can be activated
to high levels through the overexpression/activation of Ras-
activating signaling partners, such as the epidermal growth fac-
tor receptor (EGFR). Thus, there has been great interest and
excitement in the development of farnesyltransferase inhibitors
(FTIs) as a means to block Ras membrane localization and
inhibit Ras-mediated signals in tumor cells. However, the clini-
cal results obtained in the implementation of these compounds
have been generally disappointing (reviewed in Refs. [2,3]).
One potential reason may be that the identity of the relevant
clinical targets of FTI and the mechanism(s) of antitumor action
of these compounds remain unclear. Despite being initially
developed as inhibitors of Ras function, clinical and preclinical
data suggest that although activated Ras may be a target
for some of the effects of FTI on cell growth and survival,
there are likely other targets as well [4]. The impact of FTI on
Ras-mediated radioresistance is similarly complex. In H-ras–
transformed REF cells as well as human tumor cell lines that
express oncogenic H-ras, inhibition of H-Ras processing by
FTI results in radiosensitization [5]. However, we have recently
found that FTI can radiosensitize pancreatic and colorectal
cancer cell lines that express oncogenic K-Ras at concentra-
tions that inhibited posttranslational processing and activation
of wild-type H-Ras, but did not appear to alter K-Ras posttrans-
lational processing or activation [6,7]. The observation that
FTI could radiosensitize tumor cell lines that express onco-
genic K-Ras could be interpreted to mean that oncogenic
K-Ras is not a relevant target or that it is uninvolved in the
mechanism of FTI-mediated radiosensitization in pancreatic
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carcinoma cells. However, the oncogenic K-Ras–expressing
pancreatic carcinoma cell lines that were radiosensitized by
FTI alone were also radiosensitized to a similar extent by
knockdown of K-Ras expression by small interfering RNA
(siRNA) [6,7]. Moreover, neither K-Ras knockdown nor FTI
radiosensitized pancreatic carcinoma cell lines that
expressed only wild-type K-Ras [6,7].
Because activating mutations at the K-ras locus have been
postulated to contribute to tumorigenesis and radiotherapy
resistance in both pancreatic and colorectal carcinomas, it is
critically important to better define the mechanism(s) by which
potential cytotoxic and/or radiosensitizing treatments are
effected by oncogenic K-Ras signaling. In addition, the relative
contribution of the H- and N-Ras isoforms to radiation resis-
tance in cancer cells that express oncogenic K-Ras remains
unclear. Therefore, the current study seeks to further investi-
gate the target and mechanism of FTI-mediated radiosensiti-
zation in oncogenic K-Ras–expressing cancer cells and to
better define the role of other Ras isoforms in these cells.
Materials and Methods
Cells
PSN-1 cells were obtained through a material transfer
agreement with Merck & Co Inc. (West Point, PA). DLD-1
and SG-5 cells were a kind gift of Eric Stanbridge (Irvine,
CA). All other cell lines were obtained from the American
Type Culture Collection (Manassas, VA). Cells were cultured
in DMEM (Life Technologies, Rockville, MD) supplemented
with 10% FBS (HyClone, Logan, UT), penicillin (100 U/ml),
and streptomycin (100 mg/ml; Life Technologies, Inc., Rock-
ville, MD) and maintained at 37jC in water-saturated 5%
carbon dioxide–95% air. Cells were regularly tested by poly-
merase chain reaction (PCR) to ensure the absence of
Mycoplasma contamination.
Inhibitors and siRNA
Tipifarnib (R115777) was obtained from Janssen Research
(Johnson and Johnson, Springhouse, PA). Gefitinib was ob-
tained from AstraZeneca (Wilmington, DE). Tipifarnib and
gefitinib were dissolved as concentrated stock solutions in
DMSO and diluted at the time of treatment with medium. Con-
trol cells were treated with medium containing an equal
concentration of DMSO or nonspecific IgG, as indicated.
SMARTpool siRNA directed against control (nonspecific) and
specific (K-Ras, cat no. M-005069-00; H-Ras, cat no.
M-004142-00; N-Ras, cat no. M-003919-00; EGFR, cat no.
M-003114-01) targets were purchased from Dharmacon
(Lafayette, CO).
Treatment of Cells before Clonogenic Cell Survival Assays
For experiments with siRNA, cells were seeded at 25%
confluence and cultured overnight. The next morning, cells
were transfected with 0.6 pmol of the indicated siRNA
SMARTpool duplexes (Dharmacon RNA Technologies) in
Optimem transfection medium using Oligofectamine (Life
Technologies, Rockville, MD). After 12 hours, the transfec-
tion medium was replaced with fresh, prewarmed culture
medium. Cultures were replated as single cells 24 hours
after transfection to assure log phase growth and to facilitate
harvest of single cells for survival plating. For experiments
with inhibitors, the indicated inhibitor was added to mid log
phase cell cultures at least 24 hours after transfection for 1 to
24 hours (as indicated) before plating for survival/irradiation
and continued for 24 hours after irradiation. At that time, the
medium was replaced with drug-free medium. Control cul-
tures were also refed to control for this manipulation.
Clonogenic Cell Survival after Irradiation
Cells were treated as described above and plated as
single cells before irradiation. Cells were irradiated with a
Mark 1 cesium irradiator (J.L. Shepherd, San Fernando, CA)
at a dose rate of 1.7 Gy/min. Colonies were stained and
counted 10 to 30 days after irradiation. The surviving fraction
was calculated as follows: [numbers of colonies formed] H
[number of cells plated (irradiated)  plating efficiency
(unirradiated)]. Each point on the survival curve represents
the mean surviving fraction from at least three dishes.
Whole Cell Lysate Preparation
Cells were lysed on culture dishes with reducing Laemmli
sample buffer after rinsing once with PBS. Samples were
boiled, sheared, clarified by centrifugation at 14,000 RPM
and stored at 20jC. Protein concentrations of lysates were
determined by amido black staining.
Immunoprecipitation
Immunoprecipitation was carried out as previously de-
scribed [8]. Cells were treated as indicated, washed twice
with ice-cold PBS, and lysed in 1 ml of ice-cold lysis buffer
(1% Nonidet P-40, 100 mol/l NaCl, 50 mol/l NaF, 1 mol/l
dithiothreitol, 25 mol/l benzamidine, 1 mol/l phenylmethyl-
sulfonyl, fluoride, 2 mg/ml aprotinin, 2 mg/ml leupeptin,
2 mol/l sodium orthovanadate and 50 mol/l Tris, pH 7.4).
Proteins concentrations were determined using the Bio-Rad
Protein Assay Reagent according to manufacturer’s instruc-
tions. One milligram of total cell protein was immunoprecipi-
tated from each lysate using 4 mg of anti-EGFR (1 mg/ml) for
15 hours at 4jC. The resultant immune complexes were
washed four times in ice-cold lysis buffer and resuspended in
reducing Laemmli sample buffer for Western blot analysis.
SDS-PAGE and Western Blot Analysis
For total cell proteins, equal amounts of protein were
separated by SDS-PAGE under denaturing conditions and
blotted onto nitrocellulose membranes (Bio-Rad Laboratories,
Hercules, CA). Membranes were blocked in PBS containing
0.1% Tween 20 and 5% powdered milk before the addition of
primary antibody. N-Ras and H-Ras antibodies (Oncogene
Research products, La Jolla, CA) were used at a dilution of
1:5000; K-Ras antibody (Santa Cruz Biotechnology, Santa
Cruz, CA) was used at a dilution of 1:100; b-actin clone AC-15
(Sigma, St. Louis, MO) was used at 1:5000 dilution; and
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EGFR antibody (Cell Signaling, Danvers, MA) was used at
a dilution of 1:1000. Antibody binding was detected by using
the ECL chemiluminescence kit and Hyperfilm (Amersham,
Arlington Heights, IL). Hyperfilm images were digitized using
an AGFA Arcus II scanner (AGFA, Ridgefield Park, NJ),
and figures were assembled using Adobe Photoshop and
Microsoft PowerPoint.
Results
Our prior studies have shown that signaling through onco-
genic H-, K-, and N-Ras can all contribute to tumor cell
radiation survival. Wild-type H-Ras can also promote cellular
radioresistance when overexpressed or activated by recep-
tor signaling. Therefore, we examined the contribution of the
three main Ras isoforms (N, H, and K) to radiosensitivity and
FTI-mediated radiosensitization in pancreatic and colorectal
cancer cells that have K-Ras oncogenic mutations. In these
experiments, we have used tipifarnib, a compound that is
highly selective for FTI over geranylgeranyltransferase in-
hibitor activity, in combination with genetic deletion and
siRNA expression knockdown to separate the contributions
of the Ras isoforms to radiation survival.
Tipifarnib and other FTIs when used alone can radio-
sensitize most, but not all, pancreatic and colorectal carci-
noma cell lines that express oncogenic K-Ras, despite
having no detectable effect on K-Ras processing or activa-
tion at concentrations that produce radiosensitzation. In
contrast, at these concentrations H-Ras farnesylation and
activity are inhibited [6,7]. These observations raised ques-
tions regarding themechanism of radiation resistance in cells
with oncogenic K-Ras. To evaluate the contribution of onco-
genic K-Ras signaling to radiation survival, DLD-1 colorectal
carcinoma cells and the isogenic K-Ras knockout cell line
SG-5 were treated with 2.5 mmol/l tipifarnib for 24 hours
before irradiation, and clonogenic cell survival after radiation
was determined. DLD-1 cells express one oncogenic and
one wild-type copy of K-Ras. In SG-5 cells, the oncogenic
copy has been deleted by homologous recombination. Tipi-
farnib radiosensitized DLD-1 cells and tipifarnib-treated
DLD-1 cells showed a similar level of radiosensitivity com-
pared with radiosensitivity of the K-Ras knockout SG-5
Figure 1. Oncogenic K-Ras expression is necessary for FTI-mediated radiosensitization. (A) DLD-1 and SG-5 cells were pretreated for 24 hours with 2.5 mol/l
tipifarnib and clonogenic cell survival assays were performed as described in Materials and Methods. DLD-1 cells express one oncogenic and one wild-type copy
of K-Ras. In SG-5 cells, the oncogenic copy has been deleted by homologous recombination. (B) Clonogenic cell survival assays were performed on MiaPaCa-2
cells that were transfected with either nonspecific siRNA (control) or siRNA directed against K-Ras 48 hours before irradiation and then treated with or without
2.5 mol/l tipifarnib 24 hours before irradiation as described in Materials and Methods. (C) Cells were treated as in (B) (without irradiation) and whole-cell lysates
were analyzed by Western blot with the indicated antibody as described in Materials and Methods. C, control; K, K-Ras siRNA. (D) Western blot analysis of
whole-cell lysates 48 hours after transfection with either control (con) or K-ras–specific (K-Ras) siRNA probed with antibodies specific for the K, H or N-Ras
isoforms, as indicated.
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cell line (Figure 1A). However, tipifarnib did not radiosen-
sitize SG-5 cells (Figure 1A). Analogous results were
obtained using siRNA to specifically inhibit K-Ras expression
in MiaPaCa-2 cells (homozygous oncogenic K-RasG12C) in
which loss of oncogenic K-Ras expression resulted in de-
creased radiation survival, and tipifarnib treatment did not
cause additional radiosensitzation after K-Ras knockdown
(Figure 1, B and C). We have also verified the isoform
specificity of K-Ras knockdown in these cells (Figure 1D).
We next evaluated the impact of wild-type H-Ras on
radiation survival in carcinoma cell lines that express onco-
genic K-Ras. In the cell lines sensitized by FTI treatment,
H-Ras knockdown resulted in radiosensitization (Figure 2,
A and B). This radiosensitization is similar in magnitude
to the radiosensitization provided by FTI (Figure 1) [6,7].
Importantly, H-Ras knockdown failed to radiosensitize
PSN-1, a pancreatic carcinoma cell line that is radiosensi-
tized by K-Ras knockdown but is not sensitized by FTI alone
Figure 2. FTI and knockdown of wild-type H-Ras expression lead to nonadditive radiosensitization of cells that express mutant K-Ras. (A) Clonogenic cell survival
assays were performed using MiaPaCa-2 and DLD-1 cells that were transfected with either nonspecific siRNA (control) or siRNA directed against H-Ras 48 hours
before irradiation as described in Materials and Methods. (B) Summary of the results from clonogenic cell survival assays comparing survival after transfection of
pancreatic and colorectal carcinoma cells with nonspecific siRNA to survival after transfection with H-ras specific siRNA. Radiosensitization was scored positive
(indicated by ‘‘+’’) if the survival ratio for control/H-ras siRNA exceeded 1.1 at both 2 Gy and at 10% clonogenic cell survival. For comparison, the ability of FTI to
radiosensitize these cell lines in previous studies is similarly indicated. (C) Clonogenic cell survival assays were performed on MiaPaCa-2 cells that were
transfected with either nonspecific siRNA (control) or siRNA directed against H-Ras 48 hours before irradiation and then treated with or without 2.5 mol/l tipifarnib
24 hours before irradiation as described in Materials and Methods. (D) Cells were treated as in (C) (without irradiation) and whole cell lysates were analyzed
by Western blot with the indicated antibody as described in Materials and Methods. Effects of FTI on H-Ras processing are noted as unprocessed (UP) and
processed (P) H-Ras proteins. C, control siRNA; H, H-ras–specific siRNA. (E) Western blot analysis of whole-cell lysates 48 hours after transfection with either
control (con) or H-ras–specific (H-Ras) siRNA probed with antibodies specific for the K, H, or N-Ras isoforms, as indicated.
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(Figure 2B) [6,7]. Moreover, H-Ras knockdown did not
radiosensitize BxPC-3, a pancreatic cancer cell line that
expresses only wild-type K-ras (Figure 2B). The combination
of tipifarnib + H-Ras knockdown did not produce a greater
degree of radiosensitization than either agent alone (Fig-
ure 2, C and D). We have also verified the isoform specificity
of H-Ras knockdown in these cells (Figure 2E ).
To determine whether N-Ras similarly contributes to radio-
sensitivity in cells that express oncogenic K-Ras, we exam-
ined the impact of N-Ras knockdown on MiaPaCa-2 cells.
These experiments showed that N-Ras knockdown did not
promote radiosensitization and did not interfere with tipifarnib-
mediated radiosensitization (Figure 3, A and B). As a control
for knockdown specificity, we have verified that knockdown
with the N-Ras siRNA pool was specific for the desired Ras
isoform (Figure 3C). In addition, whereas the experiments in
Figures 1 to 3 use Dharmacon SMARTpool siRNAs to achieve
isoform-specific knockdown, we have obtained similar re-
sults using self-designed siRNA that are complimentary to dif-
ferent areas of the K- and H-Ras primary sequences (data not
shown). Together these data indicate that wild-type H-Ras,
but not N-Ras, has a role in determining the radiosensitivity of
cells expressing oncogenic K-Ras.
Autocrine activation of EGFR by transforming growth fac-
tor (TGF)a occurs in response to transfection of rat intestinal
epithelial cells transfected with oncogenic K-ras [9]. In addi-
tion, TGFa has been shown to activate EGFR-dependent
H-Ras signaling in pancreatic cancer cells that express mu-
tant K-ras [10] and antibodies to TGFa have been shown to
radiosensitize oncogenic K-Ras–expressing A549 cells [11].
Therefore, we hypothesized that wild-type H-Ras that is
stimulated by EGFR activation is the target of FTI-mediated
radiosensitization in cells that express oncogenic K-Ras. In
initial experiments, gefitinib inhibition of EGFR activation was
used to test this model. Gefitinib-mediated inhibition of EGFR
activation radiosensitized oncogenic K-Ras–expressing pan-
creatic carcinoma cells and radiosensitization by gefitinib was
not additive to K-Ras knockdown (Figure 4A). These results
are in agreement with data that EGFR inhibitors can radio-
sensitize other cells that express oncogenic K-Ras, but impli-
cate oncogenic K-Ras as a contributor to EGFR-mediated
radioresistance [11–13]. We have also found that cetuximab,
an immunoglobulin-derived EGFR inhibitor, radiosensitizes
DLD-1 cells (data not shown).
One potential concern with these EGFR inhibitor studies
is that there may be off-target effects, such as inhibition of
other HER family members that complicate experimental
interpretation. To more specifically assess the contribution
of the EGFR signaling to radiation survival in oncogenic
K-Ras–expressing cells, an siRNA approach was used.
In these experiments, EGFR knockdown radiosensitized
MiaPaCa-2 cells and the combination of EGFR knockdown
with tipifarnib treatment did not radiosensitize cells more
than either agent used alone (Figure 4, B and C). These
results confirm the experiments with gefitinib and suggest
that tipifarnib inhibition blocks cell signaling initiated at the
EGFR. Therefore, we tested whether activation of EGFR
by the addition of exogenous TGFa could reverse the radio-
sensitive phenotype of K-Ras knockdown cells. In these
experiments, TGFa added to cell cultures 24 hours after
transfection with control or K-Ras–specific siRNA (24 hours
before irradiation) was able to completely reverse the ability
of K-Ras knockdown to radiosensitize pancreatic cancer
cells (Figure 4D). Taken together, these findings suggest
that oncogenic K-Ras promotes H-Ras activation by EGFR,
leading to enhanced radiation survival.
Discussion
We and others have shown that the activation of H-Ras,
either by mutation or EGFR activation, leads to increased
phosphatidyl inositol 3V-kinase (PI3K)/Akt-mediated radio-
resistance in a variety of human and rodent cell lines (re-
viewed in Refs. [2,14]). In cells that express oncogenic
K-ras, inhibiting K-Ras function with a combination of FTI/
geranylgeranyltransferase inhibitor, siRNA knockdown, or
genetic deletion leads to increased radiosensitivity of cancer
cells [6,15–20]. Recently, we found that FTI alone can radio-
sensitize some, but not all, oncogenic K-Ras–expressing
colorectal and pancreatic cancer cell lines [6,7], raising
questions about the role of K-Ras activity in radiation sur-
vival. In the present study, we have shown that the mecha-
nism for this radiosensitization involves FTI-mediated H-Ras
Figure 3. Expression of N-Ras is not necessary for FTI-mediated radiosen-
sitization. (A) Clonogenic cell survival assays were performed on MiaPaCa-2
cells after transfection with control or N-Ras–specific siRNA 48 hours before
irradiation followed by treatment with or without 2.5 mol/l tipifarnib 24 hours
before irradiation. (B) Cells were treated as in (A) (without irradiation) and
whole-cell lysates were analyzed by Western blot with the indicated antibody
as described in Materials and Methods. C, control siRNA; N, N-ras–specific
siRNA. Effects of FTI on N-Ras processing are noted as unprocessed (UP)
and processed (P) N-Ras proteins. (C) Western blot analysis of whole-cell
lysates 48 hours after transfection with either control (con) or N-ras–specific
(N-Ras) siRNA probed with antibodies specific for the K, H, or N-Ras iso-
forms, as indicated.
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inhibition. We have further demonstrated that oncogenic
K-Ras promotes radiation survival through EGFR signaling.
In our studies, inhibition of EGFR signaling through either
gefitinib or siRNA led to increased radiosensitivity in onco-
genic K-Ras–expressing cells. These data are in agreement
with studies from several other investigators showing that
EGFR inhibitors can radiosensitize cells that express onco-
genic K-Ras [11–13]. Moreover, promising results have
been obtained from preliminary clinical trials of combined
EGFR inhibitor plus chemoradiotherapy for patients with
Figure 4. Signaling though EGFR determines radiation survival in cells that express oncogenic K-Ras. (A) Clonogenic cell survival assays were performed on
MiaPaCa-2 cells that were transfected with or without 10 mol/l gefitinib 24 hours before irradiation as described in Materials and Methods. In parallel samples
(without irradiation), EGFR was immunoprecipitated and Western blot analysis with an antiphosphotyrosine antibody was performed as described in Materials and
Methods. (B) Clonogenic cell survival assays were performed on MiaPaCa-2 cells after transfection with control or EGFR specific siRNA 48 hours before irradiation
followed by treatment with or without 2.5 mol/l tipifarnib 24 hours before irradiation. (C) Cells were treated as in (B) (without irradiation) and whole-cell lysates were
analyzed by Western blot with the indicated antibody as described in Materials and Methods. C, control siRNA; E, EGFR-specific siRNA. (D) Clonogenic cell
survival assays were performed on MiaPaCa-2 cells after transfection with control or K-Ras specific siRNA 48 hours before irradiation followed by treatment with
or without 200 pmol/l TGFa 24 hours before irradiation. (E) Clonogenic cell survival assays were performed on MiaPaCa-2 cells after transfection with control or
H-Ras–specific siRNA 48 hours before irradiation followed by treatment with or without 200 pmol/l TGFa 24 hours before irradiation.
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pancreatic cancer [21]. However, it had been previously
unclear how a cell line with a mutation that is supposedly
‘‘downstream’’ can be sensitized by inhibiting the ‘‘up-
stream’’ receptor. Our data suggest that the mechanism
that underlies this phenomenon is the ability of oncogenic
K-Ras to activate EGFR-mediated signaling through wild-
type H-Ras.
This mechanism helps to explain the previously observed
discrepancies between Ras mutation status and FTI sensi-
tivity in cancer cells. However, it is important to point out
that the target and mechanism of FTI-mediated cellular
radiosensitization are not necessarily the same as the tar-
get and mechanism of FTI-mediated cellular cytotoxicity or
growth inhibition. In this respect, it is interesting to note
that addition of an EGFR inhibitor to gemcitabine chemo-
therapy produced a relative increase of 25% in 1-year sur-
vival in patients with pancreatic cancer (absolute increase
from 17% to 24%) [22,23]. It is unclear whether K-Ras–
mediated activation of EGFR alone is sufficient to promote
EGFR inhibitor–mediated direct cytotoxicity. In one study of
a panel of EGFR-expressing pancreatic cancer cell lines,
coexpression of Erb-B3 was found to be a better predictor of
EGFR inhibitor–mediated cytotoxicity than Ras status or
EGFR expression level [24]. Thus, the potential contribution
of oncogenic K-Ras–mediated EGFR activation to pancre-
atic and colorectal cancer biology and response to therapy
requires further investigation.
Despite our current findings, the role of the various Ras
isoforms in cellular radiosensitivity similarly requires fur-
ther study. Some oncogenic K-Ras–expressing cell lines
are clearly radiosensitized by inhibiting either K-Ras or
PI3K/Akt activation [6,18,19,25]. However, other oncogenic
K-Ras–expressing cell lines appear to be less sensitive to
PI3K inhibition [20,26]. In addition, transfection of oncogenic
K-Ras into Rat-2 cells results in increased radiosensitivity,
possibly through a p38 mitogen-activated protein kinase
(MAPK)–dependent mechanism [27]. One potential expla-
nation for this phenomenon lies in genetic heterogeneity of
these systems. It seems likely that the phenotype of cells
that express activated Ras isoforms will depend, at least
to some extent, on the levels of coexpression of different
Ras interacting signaling partners. Our results predict that
EGFR would be one such partner. Another possibility lies in
the differential subcellular localization of Ras isoforms when
expressed at different levels. At low expression levels, acti-
vated H- and K-Ras localize to distinct, non–cholesterol-
containing plasma membrane microdomains, and this may
be one mechanism of the observed preference of H-Ras for
activating PI3K > MAPK, whereas K-Ras activates MAPK >
PI3K [28]. However, at higher H- or K-Ras expression levels
this confined localization begins to break down [28,29]. Thus,
at different expression levels or in different cellular contexts,
H- and K-Ras activation may lead to differential activation
of signaling partners such as PI3K and MAPK. In this con-
text, it is interesting to note that the oncogenic K-Ras–
expressing cell line PSN-1 that was not radiosensitized by
FTI alone has a very high level of oncogenic K-Ras expres-
sion (unpublished observations).
In conclusion, our data are consistent with a model in
which oncogenic K-Ras leads to activation of EGFR and
H-Ras to promote cellular radioresistance. In addition, these
results indicate that H-Ras is a target of FTI-mediated radio-
sensitization in cells that express oncogenic K-Ras. These
results have significant implications for targeting cellular sur-
vival signals in tumors expressing oncogenic K-Ras.
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